-
Je něco špatně v tomto záznamu ?
Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo
L. Beckert, L. Kostka, E. Kessel, A. Krhac Levacic, H. Kostkova, T. Etrych, U. Lächelt, E. Wagner,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- amidy chemie MeSH
- DNA chemie MeSH
- methakryláty chemie MeSH
- myši MeSH
- technika přenosu genů * MeSH
- techniky in vitro MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
We report novel pH-reversibly surface-shielded polyplexes with enhanced gene transfer activity upon systemic administration. A four-arm-structured sequence-defined cationic oligomer KK[HK[(H-Sph-K)3HC]2]2 was designed and synthesized on solid-phase, containing additional lysine residues not only for improved pDNA polyplex stability, but also providing attachment points for subsequent polyplex functionalization with amine-reactive shielding polymers. Herein, the surface of polyplexes was shielded with hydrophilic polymers, monovalent PEG or monovalent and multivalent pHPMA, optionally attached to the polyplex via the acid-labile linker AzMMMan. Overall, surface modification with PEG or pHPMA resulted in a decrease in the zeta potential of polyplexes, consistent with the degree of surface shielding. At pH 6.0, only polyplexes modified via the acid-labile linkage showed an increase in zeta potential, consistent with a "deshielding" in acidic environment, expected as beneficial for endosomal escape. Shielding was more efficient for multivalent pHPMA (20kDa, 30kDa) as compared to monovalent pHPMA (10kDa, 20kDa, 30kDa) or PEG (5kDa). In vitro transfection studies revealed higher gene expression by the polyplexes with the acid-labile shield as compared to their irreversibly shielded counterparts. Intravenous administration of AzMMMan-pHPMA modified polyplexes in an in vivo tumor mouse model mediated enhanced gene expression in the subcutaneous tumor and reduced undesirable expression in the liver.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013822
- 003
- CZ-PrNML
- 005
- 20170502100805.0
- 007
- ta
- 008
- 170413s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpb.2016.05.019 $2 doi
- 035 __
- $a (PubMed)27235729
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Beckert, Linda $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
- 245 10
- $a Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo / $c L. Beckert, L. Kostka, E. Kessel, A. Krhac Levacic, H. Kostkova, T. Etrych, U. Lächelt, E. Wagner,
- 520 9_
- $a We report novel pH-reversibly surface-shielded polyplexes with enhanced gene transfer activity upon systemic administration. A four-arm-structured sequence-defined cationic oligomer KK[HK[(H-Sph-K)3HC]2]2 was designed and synthesized on solid-phase, containing additional lysine residues not only for improved pDNA polyplex stability, but also providing attachment points for subsequent polyplex functionalization with amine-reactive shielding polymers. Herein, the surface of polyplexes was shielded with hydrophilic polymers, monovalent PEG or monovalent and multivalent pHPMA, optionally attached to the polyplex via the acid-labile linker AzMMMan. Overall, surface modification with PEG or pHPMA resulted in a decrease in the zeta potential of polyplexes, consistent with the degree of surface shielding. At pH 6.0, only polyplexes modified via the acid-labile linkage showed an increase in zeta potential, consistent with a "deshielding" in acidic environment, expected as beneficial for endosomal escape. Shielding was more efficient for multivalent pHPMA (20kDa, 30kDa) as compared to monovalent pHPMA (10kDa, 20kDa, 30kDa) or PEG (5kDa). In vitro transfection studies revealed higher gene expression by the polyplexes with the acid-labile shield as compared to their irreversibly shielded counterparts. Intravenous administration of AzMMMan-pHPMA modified polyplexes in an in vivo tumor mouse model mediated enhanced gene expression in the subcutaneous tumor and reduced undesirable expression in the liver.
- 650 _2
- $a amidy $x chemie $7 D000577
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a DNA $x chemie $7 D004247
- 650 12
- $a technika přenosu genů $7 D018014
- 650 _2
- $a techniky in vitro $7 D066298
- 650 _2
- $a methakryláty $x chemie $7 D008689
- 650 _2
- $a myši $7 D051379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kostka, Libor $u Centre for Biomacromolecular and Bioanalogous Systems, Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry Academy of Sciences CR, v.v.i., Heyrovskeho sq. 2, Prague, Czech Republic. Electronic address: kostka@imc.cas.cz.
- 700 1_
- $a Kessel, Eva $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
- 700 1_
- $a Krhac Levacic, Ana $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
- 700 1_
- $a Kostkova, Hana $u Centre for Biomacromolecular and Bioanalogous Systems, Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry Academy of Sciences CR, v.v.i., Heyrovskeho sq. 2, Prague, Czech Republic.
- 700 1_
- $a Etrych, Tomas $u Centre for Biomacromolecular and Bioanalogous Systems, Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry Academy of Sciences CR, v.v.i., Heyrovskeho sq. 2, Prague, Czech Republic.
- 700 1_
- $a Lächelt, Ulrich $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
- 700 1_
- $a Wagner, Ernst $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany. Electronic address: ernst.wagner@cup.uni-muenchen.de.
- 773 0_
- $w MED00001640 $t European journal of pharmaceutics and biopharmaceutics official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 105, č. - (2016), s. 85-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27235729 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170502101132 $b ABA008
- 999 __
- $a ok $b bmc $g 1200287 $s 974600
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 105 $c - $d 85-96 $e 20160525 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
- LZP __
- $a Pubmed-20170413